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Summary  
 
Parkinson’s disease (PD) is a fatal neurodegenerative 
disorder that affects 1.5 millions Americans and 1 in 100 
individuals over the age of 60.  It results from neuronal 
atrophy localized within the substantia nigra pars 
compacta.  Upon autopsy, PD patients have large 
intraneuronal fibrils, Lewy Bodies, composed of α-
synuclein.  Familial forms of PD result from the A30P 
and A53T mutations within α-synuclein.  Wild-type (WT), 
A30P, and A53T-α-synuclein aggregate from monomers 
into protofibrils before forming fibrils.  Previously, fibrils 
were thought to be the PD causative agent however, 
recent evidence suggests that the protofibril may be the 
true toxic conformation of α-synuclein.  In 2004, Zarranz 
et al. discovered a novel mutation, α-synuclein-E46K, in 
a Spanish family.  Little is known about this mutation, 
except that it increases the rate and quantity of fibril 
formation as well as the lipid binding affinity of α-
synuclein.  The fibril formation pathway for E46K is 
unknown, though it likely includes a protofibrillar 
intermediate.  Future research is needed to characterize 
E46K and compare it to the other familial mutants.  
Treatment approaches aimed at reducing the 
concentration of protofibrils could be accomplished 
through accelerated fibril formation, decreased α-
synuclein expression, increased α-synuclein 
degradation, or reduction of intracellular dopamine 
which binds and stabilizes protofibril.  
 
Introduction 
 
Parkinson’s disease (PD) is a fatal neurodegenerative 
disorder of the central nervous system. It is characterized by 
motor initiation deficits, rigidity, bradykinesia, and resting 
tremor.  It affects 1 in 100 individuals over the age of 60 and 
90 to 95% of all PD cases are sporadic (NPD Foundation, 
2006).  Heritable forms of the disease constitute the 
remaining 5-10% of cases (NPD Foundation, 2006).  Within 
the whole of PD cases, another 5 to 10% occur in individuals 
under the age of 40 (NPD Foundation 2006).  For the past 
decade, millions of dollars in federal and private funding 
along with numerous researchers have provided us with a 
large body of knowledge on PD.  However, there is still no 
cure and all patients are destined to die as a result. 
 
Pathology 
 
As Dr. James Parkinson first observed in 1817, the PD brain 
is characterized by neuronal atrophy localized within the 
pars compacta region of the substantia nigra.  Most PD 
patients do not display any symptoms until 60-80% of 
substantia nigral neurons are dead (Purves et al., 2004).  
These neurons have a black coloration because they contain 
the molecule melanin (Purves et al., 2004). Upon autopsy, 
little pigmentation is observed in the substantia nigra, which 
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indicates degeneration.  At the cellular level, substantianigral 
neurons contain large intraneuronal aggregates, Lewy 
Bodies, which consist primarily of the protein α-synuclein 
(Spillantini et al., 1998).  Interestingly, aggregates are found 
only in these neurons even though α-synuclein is abundantly 
expressed throughout the human brain.  
In comparison of PD with the neurodegenerative 
disorders Alzheimer’s disease (AD), and Amyotrophic 
Lateral Sclerosis (ALS, Lou Gehrig’s), a common pathology 
is observed (Lansbury et al., 2003).  Upon autopsy, the AD 
brain is characterized by neuronal atrophy localized within 
the medial temporal lobe.  Like PD patients, the medial 
temporal neurons in AD contain large intraneuronal 
aggregates composed of the protein tau, as well as extra-
cellular β-amyloid plaques (Lansbury et al., 2003).  ALS 
patients have degeneration of α-motor neurons which also 
exhibit large intraneuronal aggregates consisting of 
superoxide dismutase-1 (SOD1) (Ray et al., 2004).  Overall, 
each of these diseases has a common pathology of protein 
misfolding and aggregation. 
This review will focus on the characteristics of α-synuclein, 
primarily misfolding and aggregation.  However, many of the 
characteristics of α-synuclein provide valuable insight into 
the proteins involved in AD and ALS.  Significant 
commonalities will be referred to within the text.  
 
Biological Basis 
 
The actual biological basis of PD remains to be discovered, 
however, mutations within several proteins have been linked 
to familial forms of PD.  PD results from the mutations A30P 
(Krueger et al., 1998), A53T (Polymeropoulos et al., 1997), 
or E46K (Zarranz et al., 2004) within the protein α-synuclein.  
It can also result from mutations within parkin (Kitada et al., 
1998), UCH-L1 (Leroy et al., 1998), PINK1 (Valente et al., 
2004), DJ-1 (Bonifati et al., 2003), and LRRK2 (Funayama et 
al., 2002).  Because A30P, A53T, and E46K mutations 
cause PD and α-synuclein is the primary component of Lewy 
Bodies, it has remained the main target of research.   
 
Systems for Modeling PD 
 
Several different systems are used for the study of PD 
including mice, drosophila, yeast, primary neuron cultures, 
and various in vitro techniques.  A line of transgenic mice 
overexpressing human α-synuclein has been established, 
and found to exhibit substantia nigral atrophy and motor 
deficits similar to those in PD (Masliah et al., 2000).  
Interestingly, these mice have Lewy Body like structures that 
differ from those found in human neurons because they are 
non-fibrillar (unorganized) aggregates (Goldberg and 
Lansbury, 2000).  In contrast, the α-synuclein aggregates in 
humans are highly organized fibrils (Lansbury et al., 2003).  
Mice expressing both human α-synuclein and its homologue, 
β-synuclein, have fewer aggregates and show no symptoms 
of PD (Hashimoto et al., 2001).  A drosophila model 
expressing human wild-type (WT), A30P, and A53T α-
synuclein has also been synthesized and found to exhibit 
aggregation, dopaminergic neuronal atrophy, and motor 
deficits (Feany and Bender, 2000).  Finally, several yeast 
models expressing human α-synuclein-WT, A30P, and A53T  
have been established (Outeiro et al., 2003; Dixon et al., 
2005; Zabrocki et al., 2005; Sharma et al., 2006; Brandis et 
al., 2006). 
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α-Synuclein 
                                                                                                    
As previously mentioned, α-synuclein is the principal 
component of Lewy Bodies and causes PD when A30P, 
A53T, or E46K mutations are present.  It is a small, 140 
amino acid, 14 kDa, natively unfolded protein, but highly α-
helical in the presence of fluorinated alcohols, detergents, or 
vesicles (Weinreb et al., 1996; Davidson et al., 1998).  α-
synuclein is divided into three distinctive regions.  The N-
terminus is amphipathic and consists of amino acids 1-60, 
which contain seven highly conserved 11-amino acid slightly 
variable repeats, XKTKEGVXXXX (Kessler et al., 2003; 
Uversky et al., 2002).  The central portion of α-synuclein is 
amyloidagenic and consists of amino acids 61-95.  It 
contains two of the above repeats above (Uversky et al., 
2002).  Finally, the C-terminus consists of amino acids 96-
140 and contains many acidic residues as well as numerous 
prolines which are characteristic of unfolded proteins 
(Uversky et al., 2002).  α-synuclein is expressed throughout 
human brains primarily in pre-synaptic terminals. There it 
may be involved in vesicular trafficking (Maroteaux et al., 
1988), regulation of neurotransmitter (Jensen et al., 1998; 
Murphy et al., 2000) as well as several other possible 
functions not listed. The actual function of α-synuclein 
remains unknown.  
 
A30P, A53T and Fibrillization 
 
Lewy Bodies are the end products of monomeric α-synuclein 
aggregation and are present in every PD brain (Purves et al., 
2004).  Initial studies of α-synuclein were directed at 
determining the mechanism by which it transformed from 
monomers into highly organized fibrils.  In order to begin this 
enormous task, Conway et al. conducted an in vitro analysis 
of A30P, and A53T to determine their rates of aggregation 
(1998).  At low concentrations of monomer, they found both 
isomers to be natively unfolded.  However, as their 
concentrations increased fibrils began to form at different 
rates depending on the isoform, with A30P fibrillizing the 
slowest and A53T the fastest (Conway et al., 1998).  In 
addition to increases in monomer concentration, increased 
molecular crowding increases the rate of fibrillization 
(Shtilerman et al., 2002).  The Conway et al. study led to the 
hypothesis that familial PD resulted from increased 
aggregation of α-synuclein (1998).   
 
Discovery and Properties of Protofibrils 
 
This “old” model quickly changed when Conway et al. 
conducted a subsequent experiment that specifically 
quantified the rate of monomeric α-synuclein disappearance 
and rate of fibril formation (2000).  At equimolar 
concentrations of A30P, A53T, WT, the rates of monomeric 
A30P and A53T consumption were increased compared to 
WT with A53T being the fastest.  In addition, a mixture of 
A30P and WT was consumed slower than A30P alone and 
A53T mixed with WT.  Interestingly, the rates of fibril 
formation for both A53T and A30P did not account for their 
rates of monomeric disappearance.  Thus, Conway et al. 
hypothesized that a protofibrillar intermediate existed (2000). 
The existence of the protofibril was confirmed using atomic 
force microscopy (AFM) and gel filtration chromatography on 
solutions of A30P, and A53T (Conway et al., 2000).  Gel 
filtration isolated oligomeric intermediates between monomer 
and fibril forms.  AFM of these protofibrils revealed them to 
exist in either a spherical conformation, chain of spheres, or 
rings of spheres.  Thus, Conway et al. revised their previous 
hypothesis by proposing that a protofibrillar intermediate was 
the causative agent in PD (2000).  If protofibrils were the 
toxic form of α-synuclein, it would account for the lack of 
A30P propensity for aggregation yet still being capable of 
causing PD.  
 Following the discovery of protofibrils, a study 
conducted by Rochet et al. compared the in vitro fibrillization 
properties of human α-synuclein-WT, A30P, and A53T to 
mouse α-synuclein (2000).  Like human α-synuclein, mouse 
α-synuclein exists in a natively unfolded structure, and has a 
threonine amino acid at the 53rd codon (Rochet et al., 2000).  
Mouse α-synuclein aggregates even faster than human 
A53T (Rochet et al., 2000).  However, mouse aggregates 
are similar because they are β-sheet rich (Rochet et al., 
2000).  Interestingly, mixtures of mouse α-synuclein with 
human WT or A53T led to the slowing of fibrillization but an 
increase in protofibril formation (Rochet et al., 2000).  These 
findings further support the hypothesis of a toxic protofibrillar 
intermediate because transgenic mice can express PD 
symptoms without organized fibril formation (Goldberg and 
Lansbury, 2000). 
 
α-Synuclein Membrane Affinity 
 
In addition to the folding, misfolding, and aggregative 
properties of α-synuclein, it also closely associates with 
lipids (Davidson et al., 1998; Jensen et al., 1998; Bussell, et 
al., 2004; Sharma et al., 2006).  Lipid affinity may be the 
result of α-synuclein’s numerous 11-amino acid repeats 
which are characteristic of many apolipoproteins (Davidson 
et al., 1998).   
 Detailed analysis of α-synuclein phospholipid 
interaction by Davidson et al. demonstrated that the α-
synuclein secondary structure stabilized into an α-helical 
conformation following binding to phospholipid bilayers 
(1998).  Furthermore, this experiment was conducted on a 
variety of vesicular sizes which revealed α-synuclein to 
preferentially bind to those 20-25 nm in diameter.  Similar 
studies using the familial mutants A30P and A53T found α-
synuclein membrane affinity to differ between the familial 
mutants (Jensen et al., 1998, Perrin et al., 2000).  The A30P 
mutation decreases α-synuclein’s ability to bind to 
membranes whereas A53T affinity is similar to WT (Jensen 
et al., 1998, Perrin et al., 2000).  These observations are 
consistent with those found in a budding yeast model 
(Sharma et al., 2006).  In budding yeast, WT and A53T are 
both found to membrane localize whereas A30P is observed 
to remain diffuse (Sharma et al., 2006).  
In depth analyses of the α-synuclein secondary 
structure have revealed the N-terminus to bind membranes 
while the C-terminus remains unbound and unfolded (Eliezer 
et al., 2001).  Specifically, amino acids 1-102 confer α-
synuclein membrane binding capabilities (Perrin et al., 
2000).  Because both A30P and A53T reside within this 
domain, it is not surprising that A30P diminishes membrane 
binding capability.  High resolution NMR spectroscopy of α-
synuclein confirmed that the N-terminus binds to lipid 
membranes and consequently acquires a helical 
conformation (Eliezer et al., 2001).  Interestingly, the C-
terminus remains unbound and unfolded suggesting it may 
be involved in binding to other molecules or vesicles (Eliezer 
et al., 2001).   
Thus, it is plausible that α-synuclein is involved in 
vesicular traffic at the pre-synaptic terminal based on two 
lines of evidence; 1) α-synuclein preferentially binds to 
vesicles 20-25 nm in diameter, which corresponds to the 
size of those carrying neurotransmitter (Davidson et al., 
1998) and 2) the C-terminus remains unfolded and free to 
associate with other vesicles or molecules (Eliezer et al., 
2001).  
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α-Synuclein Post-Translational Modification 
                                                                                                       
In a transgenic mouse model for PD, it was shown that α-
synuclein is post-translationally modified into an N-terminally 
truncated variant found only in regions of neurodegeneration 
(Lee et al., 2002; Kessler et al., 2003).  Based on this 
observation and that the N-terminus confers several of α-
synculein’s characteristics (previously described), Kessler et 
al. evaluated the significance of seven N-terminus repeat 
sequences (2003).  Two α-synuclein variations were 
synthesized; one with the addition of two additional repeats, 
and the other with two fewer repeats (both in the N-terminus) 
(Kessler et al., 2003).  Interestingly, their results indicated 
that the plus two mutants prefer a non-amyloid, α-helical 
conformation while the minus two acquired a β-sheet rich 
conformation.  This finding is significant because potentially 
pathogenic protofibrils and fibrils are β-sheet rich (Lansbury 
et al., 2003).  Therefore, the repeat sequences may have 
been highly conserved in order to protect against 
aggregation (Kessler et al., 2003).   
In AD, the APP is post-translationally modified into 
two fragments, Aβ40 and Aβ42, which are linked to familial 
forms of the disease (Lansbury et al., 2003).  It is feasible 
that a mechanism similar to this one may occur in PD 
patients, producing toxic truncated variations of α-synuclein 
(Kessler et al., 2003). 
  
Protofibril Membrane Affinity 
 
The pathway toward Lewy Body formation has been 
elucidated for WT, A30P, and A53T; however, the 
pathogenic agent has not.  Of all three (monomer, protofibril, 
and fibril) conformations α-synuclein is known to exist in, 
emerging evidence has indicated that the protofibril is the 
toxic agent.  Critical to this hypothesis was an experiment by 
Volles et al. using circular dichromism (2001).  They found α-
synuclein protofibrils to bind in a β-sheet rich structure to 
membranes isolated from rat brains.  Significantly, AFM 
revealed protofibrils to bind to membranes and permeabilize 
them (Volles et al., 2001).  Another study conducted by Ding 
et al. compared the binding affinity of protofibril and 
monomeric α-synuclein to synthetic vesicles, rat-brain 
derived membranes, and mitochondria (2002).  Though both 
monomeric and protofibril α-synuclein bind membranes, 
protofibils bound to each membrane more tightly than the 
monomers (Ding et al., 2002).  Interestingly, protofibrils 
formed pores resembling those of bacterial toxins (Volles et 
al., 2001).  In addition, both A30P and A53T 
permeabilization was greater per mole of protofibrils 
compared to WT (Volles et al., 2001).  Unlike protofibrils and 
monomers, fibrils do not bind membranes (Volles et al., 
2001; Ding et al., 2002).  Together, these studies provide 
evidence supporting the toxic protofibril hypothesis (Figure 
1). 
 
Recently Discovered E46K 
 
In 2004, Zarranz et al. discovered the autosomal dominant 
familial PD mutation α-synuclein-E46K in a Spanish family 
(2004).  Since its discovery, there have only been five 
published manuscripts on E46K out of the thousands of PD 
papers.  The first in vitro study examined the rate of E46K 
Dopaminergic Neurons 
Dopamine 
L-dopa 
Stable Protofibril 
A30P 
A53T 
Toxic Buildup 
Lashuel et al., 2002 
Substantia Nigra Courtesy of 
http://alzheimer.wustl.edu/adrc2/Research/Neuropath
ology/images/cerad_sn.bw.gif,  
Oxidation 
PD 
Figure 1:  This figure illustrates the possible relationship between PD and the substantia nigra.  L-dopa is an oxidized form of dopamine that 
has been binds and stabilizes protofibrils (Lashuel et al., 2002).  In this model, L-dopa (red) binds and stabilizes protofibrils.  The stabilized protofibrils 
have a high affinity for membranes and form pores similar to those of bacterial toxins which are depicted as AFM images from Lashuel et al., 2002.  
Those pores may alter the permeability of substantial nigral neurons consequently, causing PD. 
 
 84 
fibrillization, and lipid binding affinity (Choi et al., 2004).  
E46K formed aggregates at a faster rate than WT but similar 
to A53T (Choi et al., 2004).  The E46K fibrils were also 
conformationally different than A30P and A53T (Choi et al., 
2004).  In addition, E46K increased α-synuclein vesicular 
binding affinity whereas A30P decreased it significantly, and 
A53T slightly (Choi et al., 2004).   
Greenbaum et al. demonstrated that E46K increases α-
synuclein’s rate of fibrillization as well (2005).  Time-course 
circular dichromism  analysis of the E46K fibrillization 
process revealed α-synuclein to transition from primarily α-
helical to β-sheet as fibrils formed (Greenbaum et al., 2005).  
This transition occurred more rapidly for E46K compared to 
WT (Greenbaum et al., 2005).  
 A single in vivo analysis of E46K aggregation was 
performed by Pandey et al. using human catecholaminergic 
neuroblastoma cells (2006).  They demonstrated that 18% of 
E46K, 12% of A53T, 2% of A30P, and 6% of WT expressing 
cells contained aggregates.  Electron microscopy identified 
two types of aggregates within these neurons (Pandey et al., 
2006).  Furthermore, western analysis showed that E46K 
formed greater quantities of aggregates compared to A53T 
thus, indicating the higher propensity for E46K to aggregate 
(Pandey et al., 2006). 
 The β-sheet nature of E46K aggregates is similar 
to those of A30P and A53T (Conway et al., 2000; 
Greenbaum et al., 2005).  Therefore, it is probable that E46K 
forms β-sheet rich protofibrils before fibrils as well (Figure 2).  
However, detailed analysis of E46K fibrillization still remains 
to be conducted. 
 
α and β Synucleins 
  
The synuclein family consists of α, β, and γ homologues, all 
of which are expressed in humans (Park et al., 2003).  α and 
β synucleins are primarily expressed in the brain whereas γ-
synuclein is in the peripheral nervous system (Park et al., 
2003).  A relationship has been established between α and 
β-synuclein co-expression and α-synuclein aggregation 
(Hashimoto et al., 2001; Park et al., 2003).  Double-
transgenic mice expressing both human α and β-synucleins 
do not exhibit neuronal atrophy, aggregates, or motor deficits 
(Hashimoto et al., 2001).  In vitro, β-synuclein prevents α-
synuclein-A53T from forming protofibrils and fibrils (Park et 
al., 2003).  Analysis of β-synuclein’s relationship with the 
other familial mutants has yet to be performed.     
 
PD Specificity for the Substantia Nigra 
  
Though α-synuclein is abundantly expressed in the human 
brain, neurodegeneration is localized to the substantia nigra 
(Purves et al., 2004).  Conway et al. performed a wide 
screen of pharmaceuticals to find molecules that prevent 
fibril formation (2001).  Interestingly, catecholamines related 
to dopamine act as inhibitors of fibrillization (Conway et al., 
2001).  Furthermore, an oxidized form of dopamine, L-dopa, 
bound and stabilized protofibrils (Conway et al., 2001).  
Under oxidative conditions within substantia nigral neurons it 
is feasible that toxic protofibrils accumulate and are 
stabilized by L-dopa, consequently linking 
neurodegeneration to the substantia nigra (Conway et al., 
2001) 
 
Possibilities for Treatment 
  
After reviewing the characteristics of α-synuclein and its 
relationship to PD, several possibilities for treatment arise.  
Currently, PD is widely treated by replenishing the substantia 
nigra synaptic clefts with dopamine (Purves et al., 2004).  
However, this neither cures nor prevents neurodegeneration.  
In order to prevent or inhibit neurodegeneration, the 
concentration of dopamine in the cytoplasm could be 
reduced (Conway et al., 2001).  This would decrease the 
concentration of potentially toxic protofibrils and 
Monomer Protofibril 
PD? 
PD? 
Old 
Fibril 
A30P 
A53T 
E46K ? 
 
New 
http://alzheimer.wustl.edu/adrc2/Research/Neur
opathology/images/cerad_sn.bw.gif,  
Figure 2:  Comparison of the toxic protofibrillar hypothesis (“New”) to the toxic fibril hypothesis (“Old”).  The upper portion of the scheme 
depicts the two previously discovered familial mutants A30P and A53T, and their pathway toward fibril formation ending in possible neurodegeneration.  
The  lower part of the diagram shows E46K and what is known of it’s aggregation pathway from monomer to fibril and possibly neurodegeneration.  The 
E46K protofibril has yet to be discovered.  The image on the right is of the substantia nigra from a PD brain upon autopsy.  Adapted from White, 2006. 
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consequently prevent neuronal atrophy (Conway et al., 
2001).  Because protofibrils are not necessarily the PD 
causative agent, therapeutics aimed at increasing the 
degradation of α-synuclein or reducing its expression may 
prevent buildup of the toxic species as well.  
 
Conclusion 
 
PD affects millions of individuals world wide and is always 
fatal.  Familial forms of PD are known to result from the 
mutations A30P, A53T, and recently discovered E46K in α-
synuclein (Krueger et al., 1998; Polymeropoulos et al., 1997; 
Zarranz et al., 2004).  The transition from monomeric WT, 
A30P, and A53T to fibrillar α-synuclein includes a 
protofibrillar intermediate (Conway et al., 2000 and 2001).  
However, the pathway to fibril formation has not been 
determined for E46K.  If E46K were to fibrillize without 
forming protofibrils, this would refute the toxic protofibril 
hypothesis.  This possibility is unlikely because WT, A30P, 
and A53T all form protofibrils.  Future research is needed to 
determine the characteristics of E46K and how they 
compare to those of A30P and A53T.  Finally, the study of 
misfolding and aggregation of α-synuclein provides many 
valuable insights into PD as well as numerous other 
neurodegenerative disorders.  Currently, protofibrils have 
been identified in AD and ALS patients as well (Harper et al., 
1997; Lansbury et al. 2000; Ray et al., 2004).  
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